Ross Gerber Says 'Buy My Tokens' As Michael Saylor Hints Strategy Will Accumulate More Bitcoin
Renowned investor Ross Gerber responded to Michael Saylor on Sunday after the Strategy Inc. Chair said the company is gearing to buy more Bitcoin.
Gerber Jabs Saylor
Gerber replied to Strategy Chair Michael Saylor’s X post, “The Second Century Begins,” implying that the company is gearing up for 100 more BTC acquisitions.
“Please buy my tokens,” Gerber teased Saylor in what seemed to be a cheeky jibe at Strategy’s continued Bitcoin accumulation.
Please buy my tokens.
— Ross Gerber
Strategy Continues To Accumulate BTC Despite Pressures
As of writing, Strategy has unrealized losses of $6.3 billion on Bitcoin, the asset it has been buying with convertible debt and equity.
Moreover, Strategy's market valuation stands at $44.84 billion, while its Bitcoin holdings are valued at $48.28 billion. This means that the stock is trading at a discount to its net asset value.
The MSTR stock has tumbled nearly 60% over the past six months and became one of the most shorted large-cap U.S. stocks last month.
But that hasn’t deterred the company from halting its Bitcoin purchases. In fact, it has snapped up BTC every week since 2026 began, and recently marked its 100th purchase.
Saylor previously claimed that Strategy is "engineered" to endure an 80 to 90% drawdown and continue operating, describing its capital structure as “extremely robust.”
Price Action: At the time of writing, BTC was trading at $67,680.63, up 0.80% over the last 24 hours, according to data from Benzinga Pro.
Strategy shares closed 4.49% lower at $133.53 during Friday’s regular trading session. Year-to-date, the stock has dived 12%.
The stock exhibited weak price momentum across the short-, medium-, and long-term, earning a very low Momentum score in Benzinga's Edge Stock Rankings.
Photo courtesy: PJ McDonnell / Shutterstock.com
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
The Group of Seven major industrialized powers holds off on using strategic reserves to lower soaring oil prices
Should You Consider Purchasing, Selling, or Retaining ASML Shares with a Price-to-Earnings Ratio of 36.67?

